Clovis Luzivika Nzinga (Clovis Lusivika-Nzinga, Clovis Lusivika Nzinga)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 12

Top Topics

Health Insurance

Artificial Intelligence

High Throughput

Top Venues

Journal of viral hepatitis

Alimentary pharmacology & therapeutics

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Clémence Moreau, Marine Roux, Jérémie Riou, Clémence M Canivet, Etienne Audureau, Clovis Luzivika Nzinga, Pierre Nahon, Fabrice Carrat, Jérôme Boursier, null null, null null
Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients. Journal of viral hepatitis (2023)
Patrizia Maria Carrieri, Marc Bourlière, Vincent Di Beo, Clovis Luzivika Nzinga, Clémence Ramier, Saskia Antwerpes, Camelia Protopopescu, Jean-Marc Lacombe, Stanislas Pol, Hélène Fontaine, Abbas Mourad, Fabrice Carrat, Martin Duracinsky, Fabienne Marcellin, null null
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort). Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2023)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Luzivika Nzinga, Jérôme Nicol, Céline Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourlière, Fabrice Carrat, null null
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort. Journal of viral hepatitis (2022)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Luzivika Nzinga, Jérôme Nicol, Céline Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourlière, Fabrice Carrat, null null
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort. Journal of viral hepatitis 30 (3) (2022)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Luzivika Nzinga, Jérôme Nicol, Céline Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourlière, Fabrice Carrat, null null
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort. Journal of viral hepatitis 30 (3) (2022)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Céline Dorival, Jonathan Bellet, Dominique Larrey, Pierre Nahon, Alpha Diallo, Carole Cagnot, Clovis Luzivika Nzinga, François Téoulé, Gilles Hejblum, Marc Bourlière, Stanislas Pol, Fabrice Carrat, null null
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers. Pharmacoepidemiology and drug safety (2022)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Luzivika Nzinga, Jérôme Nicol, Céline Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourlière, Fabrice Carrat, null null
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort. Journal of viral hepatitis 30 (3) (2022)
Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Luzivika Nzinga, Jérôme Nicol, Céline Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourlière, Fabrice Carrat, null null
Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort. Journal of viral hepatitis (2022)
Stanislas Pol, Clovis Luzivika Nzinga, Hélène Fontaine, Fabrice Carrat, null null
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply. Alimentary pharmacology & therapeutics 53 (5) (2021)
Stanislas Pol, Clovis Luzivika Nzinga, Fabrice Carrat
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply. Alimentary pharmacology & therapeutics 53 (9) (2021)
Victor De Ledinghen, Clovis Luzivika Nzinga, Jean-Pierre Bronowicki, Fabien Zoulim, Dominique Larrey, Sophie Metivier, Albert Tran, Patrick Marcellin, Didier Samuel, Olivier Chazouillères, Stephane Chevaliez, Celine Dorival, Hélène Fontaine, Jean-Michel Pawlotsky, Fabrice Carrat, Stanislas Pol, null null
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. Journal of viral hepatitis 27 (10) (2020)
Clovis Luzivika Nzinga, Hélène Fontaine, Céline Dorival, Mélanie Simony, Stanislas Pol, Fabrice Carrat, null null
The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. Journal of viral hepatitis 26 (12) (2019)